inner-banner-bg

Journal of Anesthesia & Pain Medicine(JAPM)

ISSN: 2474-9206 | DOI: 10.33140/JAPM

Impact Factor: 1.8

FDA Grants Breakthrough Device Designation to AutoGenomics INFINITI Neural Response Panel for the Identification of the Risk of Opioid Dependency

Abstract

Ramanath Vairavan

June 04, 2018 AutoGenomics, Inc., based in Carlsbad, CA, announced that its INFINITI® Neural Response Panel has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA).

PDF